期刊
MOLECULAR CANCER
卷 13, 期 -, 页码 -出版社
BMC
DOI: 10.1186/1476-4598-13-112
关键词
Integrin; TGF-beta; Metastases; Lymph nodes; Lymphatic vessels
资金
- Spanish Ministry of Health [PI10/02131]
- Foundation for Applied Medical Research (FIMA), Spain
Background: Transforming Growth Factor beta (TGF-beta) acts as a tumor suppressor early in carcinogenesis but turns into tumor promoter in later disease stages. In fact, TGF-beta is a known inducer of integrin expression by tumor cells which contributes to cancer metastatic spread and TGF-beta inhibition has been shown to attenuate metastasis in mouse models. However, carcinoma cells often become refractory to TGF-beta-mediated growth inhibition. Therefore identifying patients that may benefit from anti-TGF-beta therapy requires careful selection. Methods: We performed in vitro analysis of the effects of exposure to TGF-beta in NSCLC cell chemotaxis and adhesion to lymphatic endothelial cells. We also studied in an orthotopic model of NSCLC the incidence of metastases to the lymph nodes after inhibition of TGF-beta signaling, beta 3 integrin expression or both. Results: We offer evidences of increased beta 3-integrin dependent NSCLC adhesion to lymphatic endothelium after TGF-beta exposure. In vivo experiments show that targeting of TGF-beta and beta 3 integrin significantly reduces the incidence of lymph node metastasis. Even more, blockade of beta 3 integrin expression in tumors that did not respond to TGF-beta inhibition severely impaired the ability of the tumor to metastasize towards the lymph nodes. Conclusion: These findings suggest that lung cancer tumors refractory to TGF-beta monotherapy can be effectively treated using dual therapy that combines the inhibition of tumor cell adhesion to lymphatic vessels with stromal TGF-beta inhibition.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据